Emcure subsidiary Gennova to transfer mRNA business to Immunoscript Life Science for ₹139 crore
Gennova brought out India’s first mRNA Covid vaccine
Read the full articleYou might also wanna read
Emcure Pharmaceuticals buys final 12.05% Gennova stake for ₹231.87 Crore to consolidate control.
Emcure Pharmaceuticals is acquiring the remaining 12.05% stake in Gennova Biopharmaceuticals for ₹231.87 Crore to reach 100% ownership. This
Emcure Pharma to Invest ₹231.87 Crore to Acquire 100% Control of Gennova Biopharmaceuticals
Emcure Pharmaceuticals moves from 87.95% to 100% ownership of Gennova Biopharmaceuticals for ₹231.87 crore, simplifying its corporate struct
Emcure Pharmaceuticals secures 100% control of Gennova with ₹231.87 crore final stake buy.
Emcure is acquiring the final 12.05% minority stake in Gennova for ₹231.87 crore, making it a 100% subsidiary. The move streamlines leadersh
Emcure Pharma Q4 Net Profit Surges 24% to ₹243.74 Cr Ahead of Q1 Board Meet
Emcure Pharmaceuticals is preparing for its Q1 FY27 board meeting (date unverified) following a stellar Q4 FY26 performance where net profit
CancerVax Develops Novel Smart mRNA to Harness Pre-Existing Immunity in 99% of World Population
Company completes design and in-vitro validation of a single Smart mRNA that disguises cancer as multiple viral infections simultaneously to
Global review in The Lancet confirms mRNA vaccines are safe, effective, and promising for future disease treatment
Comprehensive review brings together global evidence to strengthen public trust and counter misinformation as mRNA vaccines expand to preven
news.ubc.ca·14d agoGlobal review in The Lancet confirms mRNA vaccines are safe, effective, and promising for future disease treatment
Comprehensive review brings together global evidence to strengthen public trust and counter misinformation as mRNA vaccines expand to preven
UBC·14d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.